(Sharecast News) - Avacta Group announced on Monday that it has raised £16m through an oversubscribed equity placing to accelerate development of its oncology pipeline, as new clinical data presented at the European Society for Medical Oncology (ESMO) demonstrated strong efficacy and safety for its lead program, faridoxorubicin (AVA6000).
The AIM-traded...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE